GENEART has been elected Finalist of the "European Biotechnica Award ...

Tag : synthetic detergent
Breaking News Email Print Back Share
Aug 25 2008, 5:16 AM EST GENEART has been elected Finalist of the "European BiotechnicaAward 2008"
MARKETWIRE Aug 25, 2008 REGENSBURG, GERMANY MARKET WIRE
- The Deutsche Messe AG in Hannover (Germany) ranks the GENEART AGas one of the best European enterprises in biotechnology and lifesciences
- The exceptional innovative spirit combined with a high-performance business concept qualified the GENEART AG team for thefinal
- The renowned biotechnology prize will be awarded on October 06,2008 in Hannover
Regensburg, August 25, 2008 - The GENEART AG is one of threefinalists in the "European Biotechnica Award 2008" competition. Theaward recognizes first rate entrepreneurial accomplishments ofEuropean biotechnology companies. Only companies with anexceptional innovative spirit combined with high performancebusiness concepts are awarded with this renowned biotechnologyaward. The award ceremony is part of the opening celebration at theBIOTECHNICA 2008 on October 06 in Hannover.
GENEART AG, the global leader in gene synthesis and specialist inthe field of Synthetic Biology has advanced the way synthetic genesare produced by miles since the company was established in 1999.Synthetic genes are needed to develop modern DNA therapeutics,vaccines and industrial enzymes, for example. All genes and geneproducts distributed by the GENEART AG are "made in Germany",exclusively produced in the GENEART laboratories in Regensburg.
Professor Ralf Wagner, CEO of the GENEART AG, comments: "Our placeas a finalist in the 'European Biotechnica Award 2008' competitionacknowledges our accomplishments throughout our company history.Based on our sustained investments in research and development, wewere able to forge ahead and extend our leadership role in themarket. Most of all, our customers in biotechnology as well as inthe pharmaceutical and chemical industries profit from ourexpertise in executing increasingly complex projects, and from ourfast extension of production capacities. As a result, time tomarket intervals for example in the development of therapeutics arereduced significantly."
"With a total of Euro 100,000.00, the 'European Biotechnica Award'is the prize with the highest monetary value and the most importantaward for small and mid-sized enterprises in the Europeanbiotechnology and life sciences", explains Stephan Ph. Kuehne,member on the Managing Board of the Deutsche Messe AG, the companyinviting to the annual competition.
More information on the Biotechnica Award can be found atwww.biotechnica.de/award_d
Legal Information
This document may contain estimates, prognoses and opinions aboutcompany plans and objectives, products or services, future results,opinions about these results or opinions leading up to theseresults. All these projections into the future are subject to risk,uncertainty and unforeseeable change outside the control of theGENEART Group. Many factors may lead to actual results, whichconsiderably deviate from the given projections for these results.
About GENEART AG
In 2000, GENEART entered the gene synthesis market and has sincebecome the global market leader. Today, the company is one of theleading specialists in the Synthetic Biology field. Experts atGENEART provide key technologies for the development and productionof new therapeutics and vaccines. Customers also take advantage ofGENEART services to customize enzyme attributes, such as theattributes of enzymes used as detergent additives, and to constructbacteria, which produce complex biopolymers or break down polymers,such as synthetics, petroleum components, etc. Our production andservice spectrum spans a wide range, from the production ofsynthetic genes according to DIN EN ISO 9001-2000, to the creationof gene libraries in the combinatorial biology, to the developmentand production of DNA-based biologically active substances. TheGENEART AG in Regensburg (Germany) and the subsidiary GENEART Inc.in Toronto (Canada) employ more than 190 people. Since May 2006,GENEART is listed on the German Stock Exchange.
Copyright Copyright Hugin AS 2008. All rights reserved. For further inquiries, please contact: Bernd Merkl GENEART AGJosef-Engert-Str. 11 93053 Regensburg Germany Phone: +49-(0)941-94276-638 Fax: +49-(0)941-942 76-711 Email Contact www.geneart.com Frank Ostermair Better Orange IR & HV AG Haidelweg 48 81241Munich Germany Phone: +49-(0)89-8896906-10 Fax:+49-(0)89-8896906-66 Email Contact www.better-orange.de
SOURCE: Geneart AG Email Print Back Share